Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences (Nasdaq: AKYA) recently showcased its latest innovations in spatial biology at the second annual Spatial Day event. The company introduced ready-to-use PhenoCode panels, enhancements to the PhenoCycler-Fusion platform to double throughput, and expanded software partnerships for data analysis. Akoya's advancements aim to simplify and accelerate the discovery of spatial signatures, improving patient outcomes in precision medicine. The new products and partnerships reflect Akoya's commitment to enhancing research capabilities for clinical and translational scientists.
Akoya Biosciences (Nasdaq: AKYA) reported a strong performance for Q3 2022, with revenues of $18.9 million, marking a 40% year-over-year increase. Product revenue rose to $14.4 million, up 32%, driven by a 67% increase in instrument sales with 55 units sold. The installed base has reached 863 instruments. Year-to-date revenue is $53.6 million, up 38%. Gross profit for the quarter was $10.9 million, maintaining a 58% margin. The company has raised its full-year revenue guidance to $73-75 million due to positive growth trends and strong market execution.
Akoya Biosciences (Nasdaq: AKYA) has launched PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery on PhenoImager® platforms. These customizable multiplex panels enable phenotyping of the tumor microenvironment and immune status, streamlining biomarker validation for immuno-oncology applications. This development reflects Akoya's commitment to enhancing predictive tissue-based biomarker solutions, with a focus on accelerating research and clinical trials. Akoya will present their findings at the SITC 37th Annual Meeting in Boston from November 8-12, 2022.
Akoya Biosciences (Nasdaq: AKYA), known as The Spatial Biology Company®, announced its participation in three investor conferences. These include a fireside chat at the Stephens Annual Investment Conference on November 16, a panel at the Canaccord Genuity Annual MedTech Forum on November 17, and another fireside chat at the Piper-Sandler Annual Healthcare Conference on December 1. Live webcasts will be accessible on Akoya's website.
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its Q3 2022 financial results on November 7, 2022, after market close. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results. Interested investors are encouraged to register in advance for the call. Akoya specializes in spatial biology, offering innovative solutions for single-cell imaging and spatial phenotyping, aimed at enhancing understanding of biology and health.
Akoya Biosciences (Nasdaq: AKYA) will participate in four upcoming investor conferences, showcasing its advancements in spatial biology.
The events include:
- H.C. Wainwright 24th Annual Global Investment Conference - September 12 at 11:30 AM ET
- Morgan Stanley 20th Annual Global Healthcare Conference - September 14 at 8:35 AM ET
- Capital One Spatial Biology & Proteomics Summit - September 28 at 10:15 AM and 1:00 PM ET
- Bank of America Healthcare Innovation Forum - September 29 at 11 AM ET
Webcasts of the events will be available on Akoya's website.
Akoya Biosciences (Nasdaq: AKYA) reported a strong Q2 2022 with revenue reaching $17.9 million, a 37% year-over-year growth. Product revenue increased by 33% to $14.2 million, while services and other revenue surged 54% to $3.7 million. The company sold 60 instruments, marking a 94% increase in sales. Akoya also raised its FY 2022 revenue guidance to $71-74 million, supported by $88 million in cash and equivalents. The company expanded its credit facility by $20 million to enhance liquidity.
Akoya Biosciences (Nasdaq: AKYA), The Spatial Biology Company®, will participate in two investor conferences in August 2022. The first is the UBS Genomics 2.0 and MedTech Innovation Conference, featuring a fireside chat with CEO Brian McKelligon and CBO Niro Ramachandran on August 9th at 1:00 PM PT. The second event, the Canaccord Growth Conference, includes a panel discussion on spatial omics with CEO McKelligon on August 10th at 12:00 PM ET. Both sessions will be broadcast live and available for replay.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced that it will release its second-quarter financial results on August 8, 2022, after market close. A conference call for investors will take place at 5:00 p.m. ET to discuss these results. Investors can register for the call online and access a webcast on the company’s investor relations website. Akoya specializes in spatial phenotyping, providing advanced single-cell imaging solutions to enhance research in biology and health.
Akoya Biosciences and Acrivon Therapeutics announced a partnership to co-develop the innovative OncoSignature test, designed to identify cancer patients most likely to respond to ACR-368, a targeted oncology agent in Phase 2 trials. ACR-368 aims to treat ovarian, endometrial, and urothelial cancers, with promising results in platinum-resistant ovarian cancer. The OncoSignature will utilize Akoya’s PhenoImager technology for patient selection to enhance treatment outcomes, pending ACR-368's approval.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
